Leucemin-100

LEUCEMIN 100 direct effect on Myeloid Leukemia Cells

LEUCEMIN 100 direct action on human myeloid leukemia cells. Under the action of the LEUCEMIN 100medical preparation, a leukemia cells undergoes differentiation into a mature cells. This conclusion is based on the expression of CD11b / Integrin alpha M antigen on the surface of a leukemia cell under the influence of LEUCEMIN 100. The studies were conducted in in vitro experiments on the short-term cell cultures of HL-60 strain.

Table 85. Fig 21. Effect of LEUCEMIN 100 on the Growth Inhibition of HL-60 in Vitro 3 Days Culture (Promyelocytic Leukemia, Human) Title: MTT assay HL-60.

Effect of LEUCEMIN 100 on cell cycles cell line : HL-60 (Dose : 30μg/ml)

Fig. 22.  LEUCEMIN 100effect on cell line  HL-60 cell cycles

LEUCEMIN 100does not cause a violation of the cell cycle and the death of Human  myeloid leukemia cells. LEUCEMIN 100causes differentiation of Human  myeloid leukemia cells into a mature normal myeloid  cells.

Fig. 23. Dose dependent induction of CD11b antigen in HL-60 cells by GA-40. The HL-60 cells were treated with 3 to 30 μg/ml LEUCEMIN 100for 3 days. The viable cells were counted by tryptan blue dye exclusion test and the cells were treated with anti-CD11b FITC labeled antibody and expression of CD11b antigen was assayed by Flow cytometer.

LEUCEMIN 100direct action induces differentiation of  human myeloid leukemia cells (HL-60) into non-growing mature granulocytes. CD11b antigen is one of the  human cell surface receptor  found on polymorphonuclear leukocytes (granulocytes, mostly neutrophils), NK cells, and mononuclear phagocytes like macrophages. (Fig.23)

 

Tastimonials

LEUCEMIN 100 Monotheraphy

Acute and Chronic Myeloid Leukemia

 

1. Patient Dz.S.D., 3 years old (female).

Diagnosis:  Acute megakaryoblastic leukemia - M7 (FAB). It was carried out repeated courses of chemotherapy by scheme: BFM-ALL-90, block MNL-BFM-90AA, but full and stable remission was not reached. Physicians conclusion: state of child's health is very serious, diagnosis has no prospect, necessity of marrow transplantation. Analysis of marrow puncture: undifferentiated blasts LEUCEMIN 100 Therapy:  Single course of treatment with LEUCEMIN 100monotherapy.

Physician's Report:  At the beginning of treatment the child was in coma. After the course of treatment the child came out from hopeless state, began to walk and play with other - children. Partial remission was reached. Analysis of marrow puncture after the treatment: blasts 0 %, neutrophils - 68%, lymphocytes - 5.25%, platelets - 40.0%

Parents' Report:  The child feels well.

 

2. Patient V.T.V., 12 years old (female).

Diagnosis: Acute myelomonoblastic leukemia. It was carried out repeated chemotherapy, but full and stable remission was not reached. Child's health became very serious, no appetite, asthenia. Parents flatly refused additional chemotherapy. Physicians recommended marrow transplantation. Analysis of marrow puncture: undifferentiated blasts - 80%, neutrophils - 7%, lymphocytes - 5%, platelets - single in number.

LEUCEMIN 100- Therapy: Single course of treatment with LEUCEMIN 100 monotherapy. The treatment continues.

Physician's Report: Positive dynamics of general hematological and immunological indices. No side-effects. General condition and appetite improved. Analysis of marrow puncture: undifferentiated blasts - 15%, neutrophils - 60%, lymphocytes -36%, platelets - 51%.

Parents' Report: The child feels well.

 

 

 

3. Patient M.G.N., 13 years old (male).

Diagnosis: Acute Myeloid  leukemia. Philadelphia chromosome Ph+. It was not reached full and stable remission after chemotherapy by scheme: BFM-90, block R1M1, block R2M. Child had strong general weakness, pain, loss of weight, increased liver and spleen. Parents were strongly against additional chemotherapy and radiation. Physicians recommended marrow transplantation.  Analysis of marrow puncture: undifferentiated blasts - 89.6%, neutrophils - 6.8%, lymphocytes -3.2%, platelets - single in number.

LEUCEMIN 100 Therapy: Single course of treatment with LEUCEMIN 100monotherapy. The treatment continues.

Physician's Report: Positive dynamics of general hematological and immunological indices. No side-effects. No pain. General condition improved, activity and energy of life increased, weight gain. Analysis of marrow puncture: undifferentiated blasts - 0%, neutrophils - 36%, lymphocytes - 41%, platelets - 60%.

Parents' Report: We did not observe so good child's condition before the treatment and have great hope of the full recovery now.

 Patient 4.

 Patient 5.

Patient 6.

06.08.2018

BLAST  -  70 %

BAND - 3.0 %

SEGMENT – 7.05 %

LYM. – 4.25 %

04.04.2019

BLAST  -  0 %

BAND - 5.0 %

SEGMENT – 65 %

LYM. – 22 %

Medical & Biological Scientific - Research Center“ALEXIS” LTD

© Alexis ltd. 2015. All Rights Reserved. The use of the information on this site is subject to the terms of our Legal Notice. This site is published by Alexis ltd, which is solely responsible for its contents. Product names are trademarks of Alexis ltd. This information is intended for use by our customers, patients, and healthcare professionals. Alexis ltd recognizes that the internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside Georgia.